이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Shenzhen Kangtai Biological Products 관리

관리 기준 확인 3/4

Shenzhen Kangtai Biological Products' CEO는 Xiang Miao, Dec2021 에 임명되었습니다 의 임기는 2.5 년입니다. 는 CN¥ 30.61M 가치에 해당하는 회사 주식의 0.17% 직접 소유합니다. 30.61M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 11.8 년입니다.

주요 정보

Xiang Miao

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.6yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	11.8yrs

최근 관리 업데이트

Recent updates

Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

May 25

Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

May 03

Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%

May 01

Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion

Feb 27

CEO

Xiang Miao (51 yo)

2.6yrs

테뉴어

CN¥3,337,100

보상

Mr. Xiang Miao has been President at Shenzhen Kangtai Biological Products Co., Ltd. since December 29, 2021 and serves as its Director and served as its Vice President and Secretary.

리더십 팀

이름	위치	테뉴어	보상	소유권
Hui Zhou	Chief Financial Officer	2.6yrs	CN¥1.37m	0.012% CN¥ 2.1m
Xiang Miao	President & Non-Independent Director	2.6yrs	CN¥3.34m	0.17% CN¥ 29.4m
Jiankai Liu	VP & Non-Independent Director	2.6yrs	CN¥3.40m	0.16% CN¥ 27.9m
Jin Tao	Board Secretary	2.6yrs	CN¥955.50k	0.014% CN¥ 2.4m

2.6yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: 300601 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xiang Miao	President & Non-Independent Director	no data	CN¥3.34m	0.17% CN¥ 29.4m
Jiankai Liu	VP & Non-Independent Director	15.8yrs	CN¥3.40m	0.16% CN¥ 27.9m
Weimin Du	Chairman of the Board	15.8yrs	CN¥3.51m	25.5% CN¥ 4.4b
Zhiyun Lu	Chairman of the Supervisory Board	11.8yrs	데이터 없음	0.038% CN¥ 6.6m
Hak Ping Wu	Independent Director	2.6yrs	CN¥112.50k	데이터 없음
Feidong Wen	Vice Chairman	2.6yrs	CN¥2.11m	0.0081% CN¥ 1.4m

11.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 300601 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.8 년).

Shenzhen Kangtai Biological Products 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Insufficient new directors

Insufficient new directors

Recent updates

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shenzhen Kangtai Biological Products Co., Ltd. Announces Dividend Implementation (Cash Only) Payable on 14 June 2024

Price target decreased by 9.7% to CN¥31.40

Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

Price target decreased by 8.1% to CN¥32.78

Consensus revenue estimates increase by 10%, EPS downgraded

Price target decreased by 7.9% to CN¥34.78

Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.18 in 1Q 2023)

Shenzhen Kangtai Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion

Investor sentiment improves as stock rises 17%

Shenzhen Kangtai Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Shenzhen Kangtai Biological Products Co., Ltd. Announces Interim Profit Distribution Plan to Be Implemented (A Shares) for 2023, Payable on 13 October 2023

Shenzhen Kangtai Biological Products Co., Ltd. Approves 2023 Interim Cash Dividend

Shenzhen Kangtai Biological Products Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 9.2% to CN¥43.61

First quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.25 in 1Q 2022)

Price target decreased to CN¥45.81

Consensus EPS estimates fall by 30%

Price target decreased to CN¥45.81

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Price target decreased to CN¥50.30

Consensus EPS estimates fall by 53%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) announces an Equity Buyback for CNY 200 million worth of its shares.

Consensus forecasts updated

Shenzhen Kangtai Biological Products Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on 2 June 2022

Shenzhen Kangtai Biological Products Co., Ltd. Approves Final Cash Dividend for the Year 2021

Consensus forecasts updated

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥130

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Consensus EPS estimates increase by 10%

Now 22% undervalued after recent price drop

Price target decreased to CN¥178

Third quarter 2021 earnings released: EPS CN¥1.02 (vs CN¥0.26 in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.39 in 2Q 2020)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Administration Approval to BIOKANGTAI COVID-19 Vaccine for Phase III Clinical Trial in the Philippines

Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independently Developed and Manufactured by Shenzhen Kangtai Biological Products Co., Ltd. is Officially Initiated in Malaysia

First quarter 2021 earnings released: EPS CN¥0.037 (vs CN¥0.004 in 1Q 2020)

New 90-day low: CN¥135

New 90-day high: CN¥181

New 90-day low: CN¥149

Third quarter earnings released

New 90-day low: CN¥157

New 90-day high - CN¥225

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2020 Results on Jul 21, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령